Iterum Therapeutics plc
News
Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright
Ticker Report Iterum Therapeutics (NASDAQ:ITRM - Get Free Report)s stock had its "buy" rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They...\n more…
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
Globe Newswire FDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...\n more…
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
Globe Newswire DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral...\n more…
HC Wainwright Cuts Iterum Therapeutics (NASDAQ:ITRM) Price Target to $5.00
Ticker Report Iterum Therapeutics (NASDAQ:ITRM - Free Report) had its price objective trimmed by HC Wainwright from $6.00 to $5.00 in a report released on Thursday morning, Benzinga reports. The brokerage...\n more…
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Turn A Profit?
Simply Wall St Iterum Therapeutics plc ( NASDAQ:ITRM ) is possibly approaching a major achievement in its business, so we would like...\n more…